Macular Degeneration Agents Need Randomized Trials, Medicare Panel Says
Executive Summary
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, the Centers for Medicare & Medicaid Services' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore
You may also be interested in...
MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012
Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.
OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011